# REQUEST FOR CORRECTED FILING RECEIPT

**Applicant** 

Hart et al.

Appl. No.

10/577,627

Filed

April 28, 2006

For

ISOLATED CD4+ T CELLS

**DEFINED BY CMRF-35 AND** 

CD45RO

Art Unit

1645

CERTIFICATE OF EFS WEB TRANSMISSION

I hereby certify that this correspondence, and any other attachment noted on the automated Acknowledgement Receipt, is being transmitted from within the Pacific Time zone to the Commissioner for Patents via the EFS Web server on:

June 1, 2007

(Date)

Raymond D. Smith, Reg. No. 55,634

Commissioner for Patents P.O. Box 1450 Office of Initial Patent Examination Customer Service Center Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby request that the Official Filing Receipt, a copy of which is enclosed, be corrected to reflect the true title of ISOLATED CD4+ T CELLS DEFINED BY CMRF-35 <u>AND CD45RO</u>. Presently, the Filing Receipt incorrectly shows the title as ISOLATED CD4+ T CELLS DEFINED BY CMRF-35. The following is enclosed as evidence of the proper title:

- (X) Marked up copy of Filing Receipt
- (X) Cover page of International Application as Published.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 1,

By:

Raymond D. Smith

Registration No. 55,634

Agent of Record

Customer No. 20,995

(805) 547-5580

3822886:vb 053007



20995

2040 MAIN STREET

FOURTEENTH FLOOR **IRVINE, CA 92614** 

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS Dox 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

FILING OR 371(c) APPL NO. ART UNIT FIL FEE REC'D ATTY.DOCKET NO TOT CLMS DATE IND CLMS 10/577,627 04/28/2006 1645 3080 DAVI257.004APC 37 9

**CONFIRMATION NO. 9936** 

**FILING RECEIPT** 

\*OC000000023596057\*

Date Mailed: 04/30/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Derek Nigel John Hart, Dutton Park, AUSTRALIA; Georgina Jane Clark, Dutton Park, AUSTRALIA:

## **Assignment For Published Patent Application**

KNOBBE MARTENS OLSON & BEAR LLP

The Corporation of the Trustees of the Order of the Sisters of Mercy in Queensland, South Brisbane, AUSTRALIA

Power of Attorney: The patent practitioners associated with Customer Number 20995.

# Domestic Priority data as claimed by applicant

This application is a 371 of PCT/AU04/01493 10/28/2004

#### Foreign Applications

AUSTRALIA 2033905953 10/29/2003

If Required, Foreign Filing License Granted: 04/28/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/577.627** 

Projected Publication Date: 08/09/2007

Non-Publication Request: No

Early Publication Request: No

Title

Isolated cd4+ t cells defined by cmrf-35 and CD45RO

**Preliminary Class** 

435

# PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 12 May 2005 (12.05.2005)

PCT

(10) International Publication Number WO 2005/042729 A1

(51) International Patent Classification7;

C12N 5/08

(21) International Application Number:

PCT/AU2004/001493

- (22) International Filing Date: 28 October 2004 (28.10.2004)
- (25) Filing Language:

Linglish

(26) Publication Language:

English

(30) Priority Data: 2003905953

29 October 2003 (29.10.2003)

- (71) Applicant (for all designated States except US): THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENS-LAND [AU/AU]; Raymond Terrace, South Brisbane, Qucensland 4101 (AU).

- (74) Agents: HUGHES, E., John, L. et al.; Davies Collison Cave, I Nicholson Street, Victoria. Melbolime 3000 (AU).
- (81) Designated States tunless otherwise inducated, for every kind of national protection available): AE, AG, AL, AM, AT, AU. AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, T), TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, BS, FI, FR. GB, GR, HU, IE, IT, LU, MC, NL, PI,, PT, RO, SE, SI, SK, TR), OAPI (BF, BI, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Queensland 4101 (AU).

(72) Inventors; and

(73) Inventors/Applicants (for US only): HART, Derek, Nigel, Juhn [NZ/AU]: 3 Borva Street, Dutton Park, Queensland 4102 (AU). CLARK, Georgina, Jane [AU/AU]: 3 Borva Street, Dutton Park, Queensland 4103 (AU).

(74) Title: ISOLATED CD4+ T CELLS DEFINED BY CMRF-35 AND CD45RO

(54) Title: ISOLATED CD4+ T CELLS DEFINED BY CMRF-35 AND CD45RO

(57) Abstract: The present invention relates generally to a method for the treatment or prophylaxis of a condition which provokes, or are exacerbated by, an immunological response. The present invention further provides the provides compositive provides of dispersion of the present invention further provides compositive provides compositive provides of dispersions of the provides compositive provides of dispersions of the provides compositive provides of the provides of provoke, or are exacerbated by, an immunological response. The present invention further provides therapeutic and diagnostic agents for conditions which provoke, or are exacerbated by, an immunological response. The present invention further provides compositions of cells defining a sub-population of CD4+ T cells defined by CMRF-35 and CD45RO.